Uniloids Biosciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.54 Cr
as on 24-10-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.46 Cr
as on 24-10-2024
- Satisfied Charges ₹ 5.75 Cr
as on 24-10-2024
- Revenue 19.50%
(FY 2023)
- Profit 114.13%
(FY 2023)
- Ebitda -57.26%
(FY 2023)
- Net Worth -4.93%
(FY 2023)
- Total Assets -4.93%
(FY 2023)
About Uniloids Biosciences
The Corporate was formerly known as Uniloids Organics Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.54 Cr.
The company currently has active open charges totaling ₹16.46 Cr. The company has closed loans amounting to ₹5.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkateswara Vejju, Shyamsunder Churukanti, and Chandrasekhar Naganaboina serve as directors at the Company.
- CIN/LLPIN
U24100TG2010PTC067867
- Company No.
067867
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media
Who are the key members and board of directors at Uniloids Biosciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkateswara Vejju  | Additional Director | 11-Oct-2010 | Current |
| Shyamsunder Churukanti | Director | 08-Apr-2010 | Current |
| Chandrasekhar Naganaboina | Additional Director | 11-Oct-2010 | Current |
Financial Performance and Corporate Structure Insights of Uniloids Biosciences.
Uniloids Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.5% increase. The company also saw a substantial improvement in profitability, with a 114.13% increase in profit. The company's net worth dipped by a decrease of 4.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uniloids Biosciences?
In 2023, Uniloids Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Svas Infra Projects Private LimitedActive 13 years 4 monthsShyamsunder Churukanti is a mutual person
- S Square D Infra Projects Private LimitedActive 2 years 9 months
Shyamsunder Churukanti is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jul 2024 | ₹9.00 Cr | Open |
Axis Bank Limited Creation Date: 02 Aug 2023 | ₹3.37 M | Open |
Others Creation Date: 01 Sep 2020 | ₹7.12 Cr | Open |
How Many Employees Work at Uniloids Biosciences?
Unlock and access historical data on people associated with Uniloids Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uniloids Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniloids Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
